ReviewAnnals of medicine and surgery (2012)2024
Role of microRNA in colorectal carcinoma (CRC): a narrative review.
Review in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Pooled it
- A Systematic Review of Diagnostic Performance of Circulating MicroRNAs in Colorectal Cancer Detection with a Focus on Early-Onset Colorectal Cancer.International journal of molecular sciences · 2024Pooled it
- Diagnostic and Prognostic Value of miR-451 Expression in Colorectal Cancer: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer.Molecular oncology · 2026Article
- Review
- Therapeutic microRNAs: Mechanisms, Delivery, and Clinical Translation in Oncology.International journal of molecular sciences · 2026Review
- Expression Analysis of miRNA Profiles in Colorectal Cancer with a Bioinformatics Approach: An Emphasis on miR-4295, miR-4720-5p, miR-4773, and miR-6831-5p.Diagnostics (Basel, Switzerland) · 2026Article
- Diet-Driven Epigenetic Alterations in Colorectal Cancer: From DNA Methylation and microRNA Expression to Liquid Biopsy Readouts.Biomedicines · 2026Review
- Comprehensive Landscape of Diagnostic, Prognostic and Predictive Biomarkers in Colorectal Cancer: From Genomics to Multi-Omics Integration in Precision Medicine.Journal of personalized medicine · 2026Review
- Micro RNA in Colorectal Cancer-Potential Diagnostic and Prognostic Markers-An Updated Review.International journal of molecular sciences · 2025Review
- Exploring the prognostic role and expression patterns of FAM3A family genes in kidney renal clear cell carcinoma.Scientific reports · 2025Article
- miR-369-3p Ameliorates Inflammation and Apoptosis in Intestinal Epithelial Cells via the MEK/ERK Signaling Pathway.International journal of molecular sciences · 2025Article
- The miRNomics of antiretroviral therapy-induced obesity.Functional & integrative genomics · 2025Review
- Molecularly Imprinted Polymer Advanced Hydrogels as Tools for Gastrointestinal Diagnostics.Gels (Basel, Switzerland) · 2025Review
- Mechanisms of miRNAs (MicroRNAs) and Their Expression in Gastric Cancer.Archives of Razi Institute · 2025Review
- Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.Frontiers in immunology · 2025Review
- Advances in extracellular vesicle (EV) biomarkers for precision diagnosis and therapeutic in colorectal cancer.Frontiers in oncology · 2025Review
- miR-3065-5p and miR-26a-5p as Clinical Biomarkers in Colorectal Cancer: A Translational Study.Cancers · 2024Article
- Insights Into Colorectal Carcinoma: A Comprehensive Review of MicroRNA Expression Patterns.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are short non-coding RNAs that play a critical role in regulating gene expression by binding to target messenger RNAs (mRNAs). They were first discovered around 8 years after the identification of the first miRNA in 1993, and since then, there has been a significant increase in miRNA-related research and discoveries. MiRNAs have been implicated in various biological processes, including cancer, particularly in colorectal cancer (CRC). In CRC, miRNAs act as either oncogenes or tumor suppressors, influencing essential cellular functions such as cell proliferation, apoptosis, angiogenesis, and metastasis. The dysregulation of miRNAs in CRC can arise from different factors, leading to abnormal expression levels of their target mRNAs and subsequently affecting protein production. Consequently, miRNAs may directly target oncogenes or tumor suppressor genes, thereby contributing to cancer initiation and progression. Notably, tumors often exhibit reduced expression of mature miRNAs. In CRC research, miRNAs offer potential as diagnostic biomarkers and therapeutic targets. Specific miRNA profiles could serve as non-invasive tools for early CRC detection and risk assessment. Additionally, miRNA-based therapies present a promising approach for targeted cancer treatment by modulating miRNA expression. However, challenges related to delivery systems and long-term safety must be addressed to fully harness their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.